Status:
UNKNOWN
How to Prevent Heart Failure Readmission by Using Lung Impedance Device (HOPE-HF Study)
Lead Sponsor:
Hillel Yaffe Medical Center
Conditions:
Heart Failure Acute
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The readmission of Heart Failure (HF) patients for exacerbation HF within 30-day is unmet goal. The mail reason for readmission is excessive accumulation of fluid in patient's lung. According our data...
Eligibility Criteria
Inclusion
- Acute Heart Failure Patients Prior to Hospital Discharge
Exclusion
- No Cardiac Resynchronization Device Implanted During Current Hospitalization
- Estimated glomerular filtrating rate (GFR) less than 30 ml/min
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04080388
Start Date
September 1 2019
End Date
September 1 2021
Last Update
September 6 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hillel Yaffe Medical Center
Hadera, Israel, 38100